DRL launches Hyalosyn

Our Corporate Bureau

Hyderabad, Nov 5: Dr Reddy’s Laboratories Ltd (DRL) has announced the launch of ‘Hyalosyn’ (sodium hyaluronate), an intra-articular injection that provides relief from knee joint stiffness and immobility in patients suffering from severe osteoarthritis.

The product is launched under co-marketing arrangement with Gland Pharma, a Hyderabad-based pharmaceutical company, DRL release said.

Hyalosyn is used in an emerging therapy for osteoarthritis, known as Viscosupplementation.

Hyaluronic acid, the active substance in Hyalosyn, is a naturally occurring substance found in synovial fluid, which surrounds the joints.

The drug will be marketed as a sterile pre-filled syringe containing 20 mg/ 2 ml of sodium hyaluronate. It will provide much-needed relief to patients suffering from severe osteoarthritis and will enable them to resume their daily activities.